- Year 2 data shows similar efficacy between ORENCIA plus methotrexate ( MTX) and Humira plus MTX, consistent with the year 1 result which demonstrated comparable efficacy based on a non-inferiority endpoint for ACR 20 response
- Radiographic non-progression at 2 years was achieved by 85 percent of patients on ORENCIA plus MTX and 84 percent of patients on Humira plus MTX
- T he frequency of adverse events was overall similar in both groups; there were numerically fewer discontinuations due to adverse events, serious adverse events, serious infections, and fewer local injection site reactions in patients treated with ORENCIA plus MTX
ORENCIA® (abatacept) Shows Comparable Efficacy To Humira® (adalimumab) In Year Two Data From Head-to-Head Study In Patients With Moderate To Severe Rheumatoid Arthritis
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.